Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 8;136(15):1786-1789.
doi: 10.1182/blood.2019004685.

Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL

Neeraj Saini  1 , David Marin  1 , Celina Ledesma  1 , Ruby Delgado  1 , Gabriela Rondon  1 , Uday R Popat  1 , Qaiser Bashir  1 , Chitra M Hosing  1 , Yago Nieto  1 , Amin M Alousi  1 , Muzaffar H Qazilbash  1 , Stefan Ciurea  1 , Elizabeth Shpall  1 , Issa Khouri  1 , Hagop Kantarjian  2 , Elias Jabbour  2 , Farhad Ravandi  2 , Richard E Champlin  1 , Partow Kebriaei  1
Affiliations

Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL

Neeraj Saini et al. Blood. .

Abstract

Publisher's Note: There is a Blood Commentary on this article in this issue.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: P.K. has received research support from Amgen and Ziopharm; has served on advisory boards of Pfizer, Kite, and Novartis; and has received consulting fees from Jazz. F.R. has received research funding from BMS, Amgen, Xencor, Abbvie, and Orsenix; has served on advisory boards of BMS, Amgen, Astellas, AstraZeneca, Celgene, Orsenix, and Agios; and has received honoraria from BMS, Celgene, Astellas, Abbvie, AstraZeneca, Novartis, Orsenix, and Agios. The remaining authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
Study outcomes and practice patterns. (A) PFS and OS for the whole cohort of patients with Ph+ ALL. (B) PFS and OS for patients with Ph+ ALL who underwent allo-HCT while in CR1. (C) Dot matrix chart showing percentage of patients receiving different types of TKI. (D) Landmark analysis of patients who were in CMR status before and at 3 months after allo-HCT, with a significantly higher PFS in patients who received prophylactic TKI therapy compared with those who did not. (E) Graph showing increased incidence of relapse in patients who discontinued TKI therapy before 24 months vs those who continued for >24 months. (F) Decreasing percentage of patients who underwent transplantation while in CR1 over time.
See this image and copyright information in PMC

Comment in

References

    1. Abou Dalle I, Jabbour E, Short NJ, Ravandi F. Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Curr Treat Options Oncol. 2019;20(1):4. - PMC - PubMed
    1. Warraich Z, Tenneti P, Thai T, et al. . Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Ph+ ALL, A Systematic Review. Biol Blood Marrow Transplant. 2020;26(3):e55-e64. - PubMed
    1. Giebel S, Czyz A, Ottmann O, et al. . Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 2016;122(19):2941-2951. - PubMed
    1. Litzow MR. Allogeneic transplantation for patients with Philadelphia chromosome positive acute lymphoblastic leukemia: is it imperative in the tyrosine kinase inhibitor era? Best Pract Res Clin Haematol. 2018;31(4):357-360. - PubMed
    1. Carpenter PA, Snyder DS, Flowers MED, et al. . Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood. 2007;109(7):2791-2793. - PMC - PubMed

MeSH terms

Substances